(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.83%.
Rezolute's earnings in 2026 is -$84,228,000.On average, 12 Wall Street analysts forecast RZLT's earnings for 2026 to be -$66,481,182, with the lowest RZLT earnings forecast at -$81,591,846, and the highest RZLT earnings forecast at -$18,086,862. On average, 12 Wall Street analysts forecast RZLT's earnings for 2027 to be -$66,596,019, with the lowest RZLT earnings forecast at -$94,721,569, and the highest RZLT earnings forecast at -$25,120,642.
In 2028, RZLT is forecast to generate -$35,140,190 in earnings, with the lowest earnings forecast at -$71,275,636 and the highest earnings forecast at $31,149,596.